{"description":"Documents matching 'risk development product manufacturing process'","count":10000,"total_pages":50,"next_page_url":"https://www.federalregister.gov/api/v1/documents?conditions%5Bterm%5D=risk+development+product+manufacturing+process&format=json&page=2","results":[{"title":"Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program; Program Announcement","type":"Notice","abstract":"The Food and Drug Administration (FDA or Agency) is announcing year four of the Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP). This program facilitates the expedited CMC development of products under an investigational new drug application (IND) based on the anticipated clinical benefit of earlier patient access to the products. FDA has implemented this pilot program to assist with CMC readiness for products regulated by both the Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER) that have accelerated clinical development timelines. To accelerate CMC development and facilitate CMC readiness, the pilot features increased communication between FDA and sponsors and explores the use of science- and risk-based regulatory approaches, as applicable. This notice outlines the eligibility criteria and process for submitting a request to participate in the pilot.","document_number":"2025-16513","html_url":"https://www.federalregister.gov/documents/2025/08/28/2025-16513/chemistry-manufacturing-and-controls-development-and-readiness-pilot-program-program-announcement","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-08-28/pdf/2025-16513.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-16513.pdf?1756298755","publication_date":"2025-08-28","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"INFORMATION: \n I. Background \n <span class=\"match\">Development</span> programs for CBER- and CDER-regulated drugs and biologics intended to diagnose, treat, or prevent a serious disease or condition where there is an unmet medical need may have accelerated clinical <span class=\"match\">development</span> timelines. Yet, marketing applications for <span class=\"match\">products</span> in expedited <span class=\"match\">development</span> programs still need to meet FDA's approval standards, including <span class=\"match\">manufacturing</span> facility compliance with current good <span class=\"match\">manufacturing</span> practice (CGMP). <span class=\"match\">Products</span> with accelerated clinical <span class=\"match\">development</span> activities may face challenges"},{"title":"Onshoring Manufacturing of Drugs and Biological Products; Public Meeting; Request for Comments","type":"Notice","abstract":"The Food and Drug Administration (FDA, the Agency, or we) is announcing the establishment of a docket to solicit public comments on issues related to accelerating the establishment of new pharmaceutical manufacturing facilities in the United States. FDA is also announcing the following public meeting entitled \"Onshoring Manufacturing of Drugs and Biological Products.\" At this meeting, FDA will present a draft framework that seeks to facilitate onshoring of pharmaceutical manufacturing. Participants will then engage in a guided discussion regarding the proposed framework, its strengths, weaknesses, and opportunities. The group will also discuss additional considerations that may help overcome current challenges faced by industry to onshoring the manufacturing of pharmaceuticals, including active pharmaceutical ingredients (APIs) and finished drug and biological products, and ideas and options within the bounds of FDA's statutory authority that could facilitate such onshoring of manufacturing.","document_number":"2025-15083","html_url":"https://www.federalregister.gov/documents/2025/08/08/2025-15083/onshoring-manufacturing-of-drugs-and-biological-products-public-meeting-request-for-comments","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-08-08/pdf/2025-15083.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-15083.pdf?1754570718","publication_date":"2025-08-08","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"pharmaceutical <span class=\"match\">products</span> to facilitate the restoration of a robust domestic pharmaceutical <span class=\"match\">manufacturing</span> base. E.O. 14293 directs FDA to review existing regulations and guidance that pertain to the <span class=\"match\">development</span> of domestic pharmaceutical <span class=\"match\">manufacturing</span> and take steps to “eliminate any duplicative or unnecessary requirements . . .; maximize the timeliness and predictability of agency review; and streamline and accelerate the <span class=\"match\">development</span> of domestic pharmaceutical <span class=\"match\">manufacturing</span>.” \n In response to E.O. 14293, FDA has developed a proposal, “FDA PreCheck,”"},{"title":"Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program; Program Announcement","type":"Notice","abstract":"The Food and Drug Administration (FDA or Agency) is announcing year three of the Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP). This program facilitates the expedited CMC development of products under an investigational new drug application (IND) based on the anticipated clinical benefit of earlier patient access to the products. FDA has implemented this pilot program to assist with CMC readiness for products regulated by both the Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER) that have accelerated clinical development timelines. To accelerate CMC development and facilitate CMC readiness, the pilot features increased communication between FDA and sponsors and explores the use of science- and risk-based regulatory approaches, as applicable. This notice outlines the eligibility criteria and process for submitting a request to participate in the pilot.","document_number":"2024-21674","html_url":"https://www.federalregister.gov/documents/2024/09/23/2024-21674/chemistry-manufacturing-and-controls-development-and-readiness-pilot-program-program-announcement","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2024-09-23/pdf/2024-21674.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2024-21674.pdf?1726836324","publication_date":"2024-09-23","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"INFORMATION: \n I. Background \n <span class=\"match\">Development</span> programs for CBER- and CDER-regulated drugs and biologics intended to diagnose, treat, or prevent a serious disease or condition where there is an unmet medical need may have accelerated clinical <span class=\"match\">development</span> timelines. Yet, marketing applications for <span class=\"match\">products</span> in expedited <span class=\"match\">development</span> programs still need to meet FDA's approval standards, including <span class=\"match\">manufacturing</span> facility compliance with current good <span class=\"match\">manufacturing</span> practice (CGMP). <span class=\"match\">Products</span> with accelerated clinical <span class=\"match\">development</span> activities may face challenges"},{"title":"Lessons Learned From the Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program; Public Workshop; Request for Comments","type":"Notice","abstract":"The Food and Drug Administration (FDA, the Agency, or we) is announcing a virtual-only public workshop entitled \"Lessons Learned From the Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) Program.\" This workshop fulfills a commitment in the seventh authorization of the Prescription Drug User Fee Act (PDUFA VII) to hold a public meeting to discuss best practices and lessons learned from this pilot program. Convened by the Duke-Robert J. Margolis, MD Center for Health Policy (Duke-Margolis) and supported by a cooperative agreement between FDA and Duke-Margolis, the workshop will feature sponsors and FDA experience under this pilot program and will solicit input on future directions for FDA policy and programs to facilitate expedited CMC development of products under an investigational new drug application (IND), where indicated based upon the anticipated clinical benefits.","document_number":"2025-15799","html_url":"https://www.federalregister.gov/documents/2025/08/19/2025-15799/lessons-learned-from-the-chemistry-manufacturing-and-controls-development-and-readiness-pilot","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-08-19/pdf/2025-15799.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-15799.pdf?1755521133","publication_date":"2025-08-19","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"Background \n <span class=\"match\">Development</span> programs for the Center for Biologics Evaluation and Research (CBER)- and the Center for Drug Evaluation and Research (CDER)-regulated drugs and biologics intended to diagnose, treat, or prevent a serious disease or condition where there is an unmet medical need may have accelerated clinical <span class=\"match\">development</span> timelines. Yet, marketing applications for <span class=\"match\">products</span> in expedited <span class=\"match\">development</span> programs still need to meet FDA's approval standards, including <span class=\"match\">manufacturing</span> facility compliance with current good <span class=\"match\">manufacturing</span> practice (CGMP)"},{"title":"Buy America Requirements for Manufactured Products","type":"Rule","abstract":"This final rule amends FHWA's Buy America regulation to terminate FHWA's general waiver for manufactured products and establish Buy America requirements for manufactured products with respect to Federal-aid highway projects. The standards for applying Buy America to manufactured products are generally consistent with the Office of Management and Budget's (OMB) guidance implementing the Build America, Buy America Act (BABA) provisions of the Infrastructure Investment and Jobs Act (also known as the Bipartisan Infrastructure Law (BIL)).","document_number":"2024-31350","html_url":"https://www.federalregister.gov/documents/2025/01/14/2024-31350/buy-america-requirements-for-manufactured-products","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-01-14/pdf/2024-31350.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2024-31350.pdf?1736775916","publication_date":"2025-01-14","agencies":[{"raw_name":"DEPARTMENT OF TRANSPORTATION","name":"Transportation Department","id":492,"url":"https://www.federalregister.gov/agencies/transportation-department","json_url":"https://www.federalregister.gov/api/v1/agencies/492","parent_id":null,"slug":"transportation-department"},{"raw_name":"Federal Highway Administration","name":"Federal Highway Administration","id":170,"url":"https://www.federalregister.gov/agencies/federal-highway-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/170","parent_id":492,"slug":"federal-highway-administration"}],"excerpts":"America requirements for <span class=\"match\">manufactured</span> <span class=\"match\">products</span>, with that waiver known as the <span class=\"match\">Manufactured</span> <span class=\"match\">Products</span> General Waiver. \n See \n 48 FR 1946 (Jan. 17, 1983); 48 FR 53099 (Nov. 25, 1983). Under the <span class=\"match\">Manufactured</span> <span class=\"match\">Products</span> General Waiver, <span class=\"match\">manufactured</span> <span class=\"match\">products</span> that were permanently incorporated into Federal-aid projects did not need to be produced domestically, apart from predominantly iron or steel components of <span class=\"match\">manufactured</span> <span class=\"match\">products</span>.\n \n \n Through this rule, FHWA is establishing specific dates on which the <span class=\"match\">Manufactured</span> <span class=\"match\">Products</span> General Waiver will be terminated"},{"title":"Formaldehyde; Updated Draft Risk Calculation Memorandum; Notice of Availability and Request for Comment","type":"Notice","abstract":"The Environmental Protection Agency (EPA or \"the Agency\") is announcing the availability of and soliciting public comment on an Updated Draft Risk Calculation Memorandum (or \"Draft Memorandum\") to inform a Revised Draft Risk Evaluation for Formaldehyde Under the Toxic Substances Control Act (TSCA). The purpose of risk evaluations under TSCA is to determine whether a chemical substance presents an unreasonable risk of injury to human health or the environment, without consideration of costs or non-risk factors, including unreasonable risk to potentially exposed or susceptible subpopulations identified as relevant to the risk evaluation by EPA, under the conditions of use (COUs). Consistent with statutory obligations and Executive Order 14303, Restoring Gold Standard Science, EPA remains committed to the highest standards of scientific integrity and reliance on the best available scientific information. To that end, and after further consideration of comments raised during the scientific peer review process, EPA is reconsidering the use of certain hazard values in the formaldehyde risk evaluation. This Notice, Draft Memorandum, and the materials included in the docket provide the science and science policy basis for determining how the revised draft inhalation point of departure (POD) impacts the corresponding draft margin of exposure (MOE) estimates and the risk determination for formaldehyde under TSCA. Although the Agency is also providing a revised draft occupational exposure value, EPA is not changing its position that formaldehyde poses unreasonable risk of injury to human health. As such, the Agency is continuing work on a proposed risk management rule for formaldehyde as required by TSCA to ensure statutory deadlines are met and necessary protections are not delayed. EPA is also seeking additional information, specific to how formaldehyde is manufactured and used, which may inform the risk management of formaldehyde. After public comment, the Agency will determine if the proposed revisions discussed in this action warrant updating the Risk Evaluation for Formaldehyde under TSCA.","document_number":"2025-21776","html_url":"https://www.federalregister.gov/documents/2025/12/03/2025-21776/formaldehyde-updated-draft-risk-calculation-memorandum-notice-of-availability-and-request-for","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-12-03/pdf/2025-21776.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-21776.pdf?1764683108","publication_date":"2025-12-03","agencies":[{"raw_name":"ENVIRONMENTAL PROTECTION AGENCY","name":"Environmental Protection Agency","id":145,"url":"https://www.federalregister.gov/agencies/environmental-protection-agency","json_url":"https://www.federalregister.gov/api/v1/agencies/145","parent_id":null,"slug":"environmental-protection-agency"}],"excerpts":"final <span class=\"match\">risk</span> evaluation as a basis to determine, based on the weight of scientific evidence, whether or not the chemical presents an unreasonable <span class=\"match\">risk</span> to health or the environment under the chemical's COUs. This includes <span class=\"match\">risks</span> to subpopulations who may be at greater <span class=\"match\">risks</span> than the general population, such as children and workers. TSCA prohibits EPA from considering non-<span class=\"match\">risk</span> factors (\n e.g., \n costs/benefits) during <span class=\"match\">risk</span> evaluation.\n \n If at the end of the <span class=\"match\">risk</span> evaluation <span class=\"match\">process</span>, EPA determines that a chemical presents an unreasonable <span class=\"match\">risk</span> to health"},{"title":"Master Protocols for Drug and Biological Product Development; Draft Guidance for Industry; Availability","type":"Notice","abstract":"The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled \"Master Protocols for Drug and Biological Product Development.\" This draft guidance revises and replaces the previous draft guidance for industry of the same name issued on December 22, 2023. The draft guidance provides recommendations on the design and analysis of trials conducted under a master protocol as well as guidance on submissions to support regulatory review. The primary focus is on randomized trials utilizing a master protocol that are intended to contribute to a demonstration of safety and substantial evidence of effectiveness. The considerations in this guidance apply to a range of therapeutic areas. The draft guidance is intended to clarify the Agency's thinking on the use of master protocols in drug and biological product development.","document_number":"2026-12620","html_url":"https://www.federalregister.gov/documents/2026/06/24/2026-12620/master-protocols-for-drug-and-biological-product-development-draft-guidance-for-industry","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-06-24/pdf/2026-12620.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-12620.pdf?1782141309","publication_date":"2026-06-24","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"ACTION: \n Notice of availability. \n \n \n SUMMARY: \n The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled “Master Protocols for Drug and Biological <span class=\"match\">Product</span> <span class=\"match\">Development</span>.” This draft guidance revises and replaces the previous draft guidance for industry of the same name issued on December 22, 2023. The draft guidance provides recommendations on the design and analysis of trials conducted under a master protocol as well as guidance on submissions to support regulatory review. The primary"},{"title":"Type VII Veterinary Master File for Research and Development and Risk Reviews; Draft Guidance for Industry; Availability","type":"Notice","abstract":"The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft guidance for industry (GFI) #260 entitled \"Type VII Veterinary Master File for Research and Development and Risk Reviews.\" This draft guidance, when finalized, will describe FDA's current thinking regarding the use of Type VII Veterinary Master Files (Type VII VMFs). Type VII VMFs are appropriate for research and development of animal cells, tissues, and cell- and tissue-based products (ACTPs), gene therapies, and heritable intentional genomic alterations (IGAs) in animals.","document_number":"2024-31531","html_url":"https://www.federalregister.gov/documents/2025/01/07/2024-31531/type-vii-veterinary-master-file-for-research-and-development-and-risk-reviews-draft-guidance-for","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-01-07/pdf/2024-31531.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2024-31531.pdf?1736171121","publication_date":"2025-01-07","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"to unique regulatory considerations such as research and <span class=\"match\">development</span> of an ACTP, an IGA in an animal, gene therapy, or a <span class=\"match\">risk</span> review for an ACTP or IGA in an animal, where the information submitted is generally not intended to support <span class=\"match\">product</span> approval. The benefits of a Type VII VMF include: (1) confidential exchange of information with FDA that is not subject to user fees, (2) an opportunity for increased communication with FDA during early stages of <span class=\"match\">product</span> <span class=\"match\">development</span>, and (3) a <span class=\"match\">process</span> for reporting research studies outside of an investigational"},{"title":"Recommendations To Reduce the Risk of Transmission of Disease Agents Associated With Sepsis by Human Cells, Tissues, and Cellular and Tissue-Based Products; Recommendations To Reduce the Risk of Transmission of Mycobacterium Tuberculosis by Human Cells, Tissues, and Cellular and Tissue-Based Products; Draft Guidances for Industry; Availability","type":"Notice","abstract":"The Food and Drug Administration (FDA or the Agency) is withdrawing two final guidances entitled \"Recommendations to Reduce the Risk of Transmission of Disease Agents Associated with Sepsis by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)\" and \"Recommendations to Reduce the Risk of Transmission of Mycobacterium Tuberculosis (Mtb) by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)\" and reissuing them as draft guidances.","document_number":"2025-07752","html_url":"https://www.federalregister.gov/documents/2025/05/05/2025-07752/recommendations-to-reduce-the-risk-of-transmission-of-disease-agents-associated-with-sepsis-by-human","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-05-05/pdf/2025-07752.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-07752.pdf?1746189938","publication_date":"2025-05-05","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"Reduce the <span class=\"match\">Risk</span> of Transmission of Disease Agents Associated with Sepsis by Human Cells, Tissues, and Cellular and Tissue-Based <span class=\"match\">Products</span> (HCT/Ps)” and “Recommendations To Reduce the <span class=\"match\">Risk</span> of Transmission of \n Mycobacterium Tuberculosis \n (Mtb) by Human Cells, Tissues, and Cellular and Tissue-Based <span class=\"match\">Products</span> (HCT/Ps)” and reissuing them as draft guidances.\n \n The draft guidance entitled “Recommendations to Reduce the <span class=\"match\">Risk</span> of Transmission of Disease Agents Associated with Sepsis by Human Cells, Tissues, and Cellular and Tissue-Based <span class=\"match\">Products</span> (HCT/Ps)”"},{"title":"Request for Information Pertaining to the CFIUS Known Investor Program and Streamlining the Foreign Investment Review Process","type":"Proposed Rule","abstract":"The Office of Investment Security, within the U.S. Department of the Treasury (Treasury Department), is seeking public input on how the Committee on Foreign Investment in the United States (CFIUS) may streamline aspects of its foreign investment review process, including through the Known Investor Program as described below, while maintaining its rigorous analysis that identifies and addresses national security risk. This request for information (RFI) may inform CFIUS's development of statutory and/or regulatory reform proposals to increase efficiencies. The Treasury Department plans to make all submissions publicly available at https://www.regulations.gov.","document_number":"2026-02481","html_url":"https://www.federalregister.gov/documents/2026/02/09/2026-02481/request-for-information-pertaining-to-the-cfius-known-investor-program-and-streamlining-the-foreign","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-02-09/pdf/2026-02481.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-02481.pdf?1770385509","publication_date":"2026-02-09","agencies":[{"raw_name":"DEPARTMENT OF THE TREASURY","name":"Treasury Department","id":497,"url":"https://www.federalregister.gov/agencies/treasury-department","json_url":"https://www.federalregister.gov/api/v1/agencies/497","parent_id":null,"slug":"treasury-department"},{"raw_name":"Office of Investment Security","name":"Investment Security Office","id":603,"url":"https://www.federalregister.gov/agencies/investment-security-office","json_url":"https://www.federalregister.gov/api/v1/agencies/603","parent_id":497,"slug":"investment-security-office"}],"excerpts":"respond to any individual item or category. \n 29. What specific <span class=\"match\">process</span> efficiencies or other benefits should CFIUS provide to Known Investor Entities as part of the Known Investor Program, consistent with the Committee's case-by-case analysis of national security <span class=\"match\">risks</span>? \n Other Ways in Which CFIUS Can Streamline Its Authorities and <span class=\"match\">Processes</span> \n The Treasury Department also seeks feedback on ways CFIUS could improve efficiency in its <span class=\"match\">processes</span> including related to the case review <span class=\"match\">process</span>, non-notified transactions, mitigation, and monitoring and enforcement—while"},{"title":"Nonavailability Waiver applicable to Domestically Assembled Solar Photovoltaics (PV) Panels Referred to as “Solar Modules” Under Build America, Buy America Manufactured Product Provisions as Applied to Recipients of Department of Housing and Urban Development Federal Financial Assistance","type":"Notice","abstract":"In accordance with the Build America, Buy America Act (BABA), this notice advises that HUD is proposing to issue a temporary, limited non-availability partial waiver of the manufactured product requirements in BABA included in the Infrastructure Investment and Jobs Act (IIJA) for domestically assembled solar modules used in Federal financial assistance (FFA) awarded for infrastructure projects. This waiver covers multiple projects that HUD anticipates will involve the installation of solar modules with the intent of addressing multiple project specific non-availability waivers into one document to reduce paperwork and support administrative efficiency. The narrowly tailored BABA waiver proposed in this notice would support the establishment of a domestic solar supply chain, increase benefits for domestic solar manufacturing, and help reduce risks for vulnerable populations. HUD is seeking public comments on this proposed waiver.","document_number":"2024-30692","html_url":"https://www.federalregister.gov/documents/2024/12/26/2024-30692/nonavailability-waiver-applicable-to-domestically-assembled-solar-photovoltaics-pv-panels-referred","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2024-12-26/pdf/2024-30692.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2024-30692.pdf?1734961528","publication_date":"2024-12-26","agencies":[{"raw_name":"DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT","name":"Housing and Urban Development Department","id":228,"url":"https://www.federalregister.gov/agencies/housing-and-urban-development-department","json_url":"https://www.federalregister.gov/api/v1/agencies/228","parent_id":null,"slug":"housing-and-urban-development-department"}],"excerpts":"modules are <span class=\"match\">manufactured</span> <span class=\"match\">products</span>. Per sections 70912(6)(A) and (B) of the Act, <span class=\"match\">manufactured</span> <span class=\"match\">products</span> are considered to be produced in the United States if (i) the <span class=\"match\">manufactured</span> <span class=\"match\">product</span> was <span class=\"match\">manufactured</span> in the United States; and (ii) the cost of the components of the <span class=\"match\">manufactured</span> <span class=\"match\">product</span> that are mined, produced, or <span class=\"match\">manufactured</span> in the United States is greater than 55 percent of the total cost of all components of the <span class=\"match\">manufactured</span> <span class=\"match\">product</span>, unless another standard for determining the minimum amount of domestic content of the <span class=\"match\">manufactured</span> <span class=\"match\">product</span> has been"},{"title":"Guidance for Industry; Recommendations To Reduce the Risk of Transmission of Disease Agents Associated With Sepsis by Human Cells, Tissues, and Cellular and Tissue-Based Products; Recommendations To Reduce the Risk of Transmission of Mycobacterium Tuberculosis by Human Cells, Tissues, and Cellular and Tissue-Based Products","type":"Notice","abstract":"The final guidances entitled \"Recommendations To Reduce the Risk of Transmission of Disease Agents Associated with Sepsis by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)\" and \"Recommendations To Reduce the Risk of Transmission of Mycobacterium Tuberculosis (Mtb) by Human Cells, Tissues, and Cellular and Tissue- Based Products (HCT/Ps)\" are being revised to change the time by which FDA recommends implementation of the recommendations in the guidances.","document_number":"2025-02167","html_url":"https://www.federalregister.gov/documents/2025/02/03/2025-02167/guidance-for-industry-recommendations-to-reduce-the-risk-of-transmission-of-disease-agents","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-02-03/pdf/2025-02167.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-02167.pdf?1738331112","publication_date":"2025-02-03","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"the guidance entitled “Recommendations To Reduce the <span class=\"match\">Risk</span> of Transmission of Disease Agents Associated with Sepsis by Human Cells, Tissues, and Cellular and Tissue-Based <span class=\"match\">Products</span> (HCT/Ps)” to provide establishments making donor eligibility determinations with recommendations to reduce the <span class=\"match\">risk</span> of transmission of disease agents associated with sepsis for donors of human cells, tissues, and cellular and tissue-based <span class=\"match\">products</span>. \n \n FDA issued the guidance entitled “Recommendations To Reduce the <span class=\"match\">Risk</span> of Transmission of \n Mycobacterium Tuberculosis \n (Mtb)"},{"title":"Safety Standard for Lithium-Ion Batteries Used in Micromobility Products and Electrical Systems of Micromobility Products Containing Such Batteries","type":"Proposed Rule","abstract":"The U.S. Consumer Product Safety Commission (CPSC) issues this notice of proposed rulemaking (NPR) to address the unreasonable risk of death and injury associated with lithium-ion batteries used in micromobility products due to hazards such as thermal runaway of lithium cells, which can lead to fires, explosions, gas releases, burns, overheating, and smoke inhalation. The NPR proposes that electrical systems using lithium-ion batteries in micromobility products comply with applicable voluntary standards, with modifications. Because some micromobility products are children's products requiring third party testing, the NPR also proposes to add this rule to the list of rules that require such testing.","document_number":"2026-12749","html_url":"https://www.federalregister.gov/documents/2026/06/24/2026-12749/safety-standard-for-lithium-ion-batteries-used-in-micromobility-products-and-electrical-systems-of","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-06-24/pdf/2026-12749.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-12749.pdf?1782218725","publication_date":"2026-06-24","agencies":[{"raw_name":"CONSUMER PRODUCT SAFETY COMMISSION","name":"Consumer Product Safety Commission","id":84,"url":"https://www.federalregister.gov/agencies/consumer-product-safety-commission","json_url":"https://www.federalregister.gov/api/v1/agencies/84","parent_id":null,"slug":"consumer-product-safety-commission"}],"excerpts":" \n \n II. Micromobility <span class=\"match\">Products</span> Within the Scope of the Rule \n A. Description of Micromobility <span class=\"match\">Products</span> \n The Commission proposes to regulate lithium-ion batteries used in micromobility <span class=\"match\">products</span> and the electrical systems of micromobility <span class=\"match\">products</span> containing such batteries, including six types of micromobility <span class=\"match\">products</span>: eBikes, eScooters, eSBscooters, eSkateboards, eUnicycles, and hybrids of these <span class=\"match\">products</span>. Figure 1 shows examples of these micromobility <span class=\"match\">products</span>. \n \n \n EP24JN26.013 \n \n \n Generally, micromobility <span class=\"match\">products</span> are marketed, intended,"},{"title":"International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products; Pharmaceutical Development; Draft Guidance for Industry; Availability","type":"Notice","abstract":"The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry (GFI) #290 (VICH GL61) entitled \"Pharmaceutical Development.\" This draft guidance has been developed for veterinary use by the International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products (VICH). This draft guidance describes the suggested contents for the Pharmaceutical Development section, which provides an opportunity to present the knowledge gained through the application of scientific approaches and quality risk management to the development of a product and its manufacturing process.","document_number":"2024-09777","html_url":"https://www.federalregister.gov/documents/2024/05/06/2024-09777/international-cooperation-on-harmonisation-of-technical-requirements-for-registration-of-veterinary","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2024-05-06/pdf/2024-09777.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2024-09777.pdf?1714740330","publication_date":"2024-05-06","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"describes the suggested contents for the Pharmaceutical <span class=\"match\">Development</span> section, which provides an opportunity to present the knowledge gained through the application of scientific approaches and quality <span class=\"match\">risk</span> management to the <span class=\"match\">development</span> of a <span class=\"match\">product</span> and its <span class=\"match\">manufacturing</span> <span class=\"match\">process</span>. The Pharmaceutical <span class=\"match\">Development</span> section is intended to provide a comprehensive understanding of the <span class=\"match\">product</span> and <span class=\"match\">manufacturing</span> <span class=\"match\">process</span> for reviewers and investigators. \n FDA has participated in efforts to enhance international harmonization and is committed to seeking scientifically"},{"title":"Revising the Definition of “Manufactured Home” to Lower Housing Costs","type":"Proposed Rule","abstract":"This proposed rule would amend the definition of \"manufactured home\" in HUD's Manufactured Home Construction and Safety Standards (MHCSS), Model Manufactured Home Installation Standards (MMHIS), and Manufactured Home Installation Program (MHIP) to provide that a transportable section of a manufactured home serving as part of an upper floor of a manufactured home would not need to be transported or built on a permanent chassis.","document_number":"2026-11851","html_url":"https://www.federalregister.gov/documents/2026/06/12/2026-11851/revising-the-definition-of-manufactured-home-to-lower-housing-costs","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-06-12/pdf/2026-11851.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-11851.pdf?1781181916","publication_date":"2026-06-12","agencies":[{"raw_name":"DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT","name":"Housing and Urban Development Department","id":228,"url":"https://www.federalregister.gov/agencies/housing-and-urban-development-department","json_url":"https://www.federalregister.gov/api/v1/agencies/228","parent_id":null,"slug":"housing-and-urban-development-department"}],"excerpts":"ACTION: \n Notice of proposed rulemaking. \n \n \n SUMMARY: \n This proposed rule would amend the definition of “<span class=\"match\">manufactured</span> home” in HUD's <span class=\"match\">Manufactured</span> Home Construction and Safety Standards (MHCSS), Model <span class=\"match\">Manufactured</span> Home Installation Standards (MMHIS), and <span class=\"match\">Manufactured</span> Home Installation Program (MHIP) to provide that a transportable section of a <span class=\"match\">manufactured</span> home serving as part of an upper floor of a <span class=\"match\">manufactured</span> home would not need to be transported or built on a permanent chassis. \n \n \n DATES: \n Comment due August 11, 2026. \n \n \n ADDRESSES: "},{"title":"Revocation of Regulations Regarding the Mutual Recognition of Pharmaceutical Good Manufacturing Practice Reports, Medical Device Quality System Audit Reports, and Certain Medical Device Product Evaluation Reports: United States and the European Community","type":"Rule","abstract":"The Food and Drug Administration (FDA, Agency, or we) is issuing a final rule revoking the regulations entitled \"Mutual Recognition of Pharmaceutical Good Manufacturing Practice Reports, Medical Device Quality System Audit Reports, and Certain Medical Device Product Evaluation Reports: United States and The European Community.\" FDA is taking this action because the regulations at 21 CFR part 26 have been superseded in part by the \"United States-European Union Amended Sectoral Annex for Pharmaceutical Good Manufacturing Practices (GMPs)\" that entered into force in 2017 (2017 Amended Pharmaceutical Annex), are outdated, do not reflect current Agency practice, and are unnecessary.","document_number":"2026-03286","html_url":"https://www.federalregister.gov/documents/2026/02/19/2026-03286/revocation-of-regulations-regarding-the-mutual-recognition-of-pharmaceutical-good-manufacturing","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-02-19/pdf/2026-03286.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-03286.pdf?1771422319","publication_date":"2026-02-19","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"final rule revoking the regulations entitled “Mutual Recognition of Pharmaceutical Good <span class=\"match\">Manufacturing</span> Practice Reports, Medical Device Quality System Audit Reports, and Certain Medical Device <span class=\"match\">Product</span> Evaluation Reports: United States and The European Community.” FDA is taking this action because the \n \n regulations at 21 CFR part 26 have been superseded in part by the “United States-European Union Amended Sectoral Annex for Pharmaceutical Good <span class=\"match\">Manufacturing</span> Practices (GMPs)” that entered into force in 2017 (2017 Amended Pharmaceutical Annex), are"},{"title":"Phasedown of Hydrofluorocarbons: Reconsideration of Certain Regulatory Requirements Promulgated Under the Technology Transitions Provisions of the American Innovation and Manufacturing Act of 2020","type":"Rule","abstract":"The U.S. Environmental Protection Agency (EPA) is finalizing changes to regulations promulgated under the Technology Transitions provision of the American Innovation and Manufacturing Act of 2020 (AIM Act), which authorizes the Administrator to restrict fully, partially, or on a graduated schedule, the use of a \"regulated substance\" in the sector or subsector in which they are used. This final rule addresses administrative petitions and input received from regulated industry and other interested parties relevant to requirements and restrictions across various refrigeration and air conditioning subsectors, including: refrigerated transport--intermodal containers; industrial process refrigeration and chillers for industrial process refrigeration used in semiconductor manufacturing; retail food supermarket systems; retail food remote condensing unit systems; cold storage warehouses; refrigerated laboratory centrifuges and laboratory shakers; and condensing units in residential and light commercial air conditioning and heat pumps. This final rule also allows the inventory of residential and light commercial air conditioning and heat pump equipment that was manufactured in the United States or imported into the United States before January 1, 2025, to continue to be installed.","document_number":"2026-10387","html_url":"https://www.federalregister.gov/documents/2026/05/26/2026-10387/phasedown-of-hydrofluorocarbons-reconsideration-of-certain-regulatory-requirements-promulgated-under","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-05-26/pdf/2026-10387.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-10387.pdf?1779453914","publication_date":"2026-05-26","agencies":[{"raw_name":"ENVIRONMENTAL PROTECTION AGENCY","name":"Environmental Protection Agency","id":145,"url":"https://www.federalregister.gov/agencies/environmental-protection-agency","json_url":"https://www.federalregister.gov/api/v1/agencies/145","parent_id":null,"slug":"environmental-protection-agency"}],"excerpts":"238220; Plumbing, Heating, and Air Conditioning Contractors \n • 325120; Industrial Gas <span class=\"match\">Manufacturing</span> \n • 333242; Semiconductor Machinery <span class=\"match\">Manufacturing</span> \n • 333415; Air Conditioning and Warm Air Heating Equipment and Commercial and Industrial Refrigeration Equipment <span class=\"match\">Manufacturing</span> \n • 333998; All Other Miscellaneous General Purpose Machinery <span class=\"match\">Manufacturing</span> \n • 334413; Semiconductor and Related Device <span class=\"match\">Manufacturing</span> \n • 335220; Major Household Appliance <span class=\"match\">Manufacturing</span> \n • 423620; Household Appliances, Electric Housewares, and Consumer Electronics Merchant"},{"title":"Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products; Revised Draft Guidance for Industry; Availability","type":"Notice","abstract":"The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a revised draft guidance for industry titled \"Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products.\" FDA has revised and is reissuing this draft guidance in response to public comments and to changes in drug development by focusing on generating rigorous scientific evidence in the most efficient manner. Advances in our understanding of biological processes and the increasing availability of high-quality data have transformed the evidentiary landscape for drug development. Given these advances, the draft guidance discusses the many factors that can impact the strength of evidence of effectiveness for a drug and clarifies how sponsors can rely on one adequate and well-controlled clinical investigation with confirmatory evidence to satisfy the substantial evidence of effectiveness standard. When final, this guidance will replace the 1998 guidance titled \"Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products.\"","document_number":"2026-12622","html_url":"https://www.federalregister.gov/documents/2026/06/24/2026-12622/demonstrating-substantial-evidence-of-effectiveness-for-human-drug-and-biological-products-revised","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-06-24/pdf/2026-12622.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-12622.pdf?1782141309","publication_date":"2026-06-24","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"“Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological <span class=\"match\">Products</span>.” FDA has revised and is reissuing this draft guidance in response to public comments and to changes in drug <span class=\"match\">development</span> by focusing on generating rigorous scientific evidence in the most efficient manner. Advances in our understanding of biological <span class=\"match\">processes</span> and the increasing availability of high-quality data have transformed the evidentiary landscape for drug <span class=\"match\">development</span>. Given these advances, the draft guidance discusses the many factors that can impact"},{"title":"1,2-Dichloroethane; Draft Risk Evaluation Under the Toxic Substances Control Act (TSCA); Notice of Availability and Request for Comment","type":"Notice","abstract":"The Environmental Protection Agency (EPA or Agency) is announcing the availability of and seeking public comment on a draft risk evaluation under the Toxic Substances Control Act (TSCA) for 1,2- dichloroethane (CASRN 107-06-2). The purpose of risk evaluations under TSCA is to determine whether a chemical substance presents an unreasonable risk of injury to health or the environment under the conditions of use (COUs), including unreasonable risk to potentially exposed or susceptible subpopulations identified as relevant to the risk evaluation by EPA, and without consideration of costs or non-risk factors. EPA used the best available science to prepare this draft risk evaluation and to preliminarily determine, based on the weight of scientific evidence, that 1,2-dichloroethane poses unreasonable risk to human health and the environment driven primarily by certain COUs analyzed in the draft risk evaluation.","document_number":"2025-20240","html_url":"https://www.federalregister.gov/documents/2025/11/19/2025-20240/12-dichloroethane-draft-risk-evaluation-under-the-toxic-substances-control-act-tsca-notice-of","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-11-19/pdf/2025-20240.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-20240.pdf?1763473508","publication_date":"2025-11-19","agencies":[{"raw_name":"ENVIRONMENTAL PROTECTION AGENCY","name":"Environmental Protection Agency","id":145,"url":"https://www.federalregister.gov/agencies/environmental-protection-agency","json_url":"https://www.federalregister.gov/api/v1/agencies/145","parent_id":null,"slug":"environmental-protection-agency"}],"excerpts":"EPA from considering non-<span class=\"match\">risk</span> factors (\n e.g., \n costs/benefits) during <span class=\"match\">risk</span> evaluation.\n \n If EPA determines in its final <span class=\"match\">risk</span> evaluation that a chemical presents an unreasonable <span class=\"match\">risk</span> to health or the environment, the chemical will move to <span class=\"match\">risk</span> management action under TSCA section 6(a) for the relevant COUs. EPA would be required to implement, via regulation, regulatory restrictions on the <span class=\"match\">manufacture</span> (including import), <span class=\"match\">processing</span>, distribution, use or disposal of the chemical to eliminate the identified unreasonable <span class=\"match\">risk</span>. TSCA section 6(a) includes"},{"title":"Procedures for Chemical Risk Evaluation Under the Toxic Substances Control Act (TSCA)","type":"Proposed Rule","abstract":"The U.S. Environmental Protection Agency (EPA, \"the Agency\") is proposing to amend the procedural framework rule for conducting existing chemical risk evaluations under the Toxic Substances Control Act (TSCA). When conducting an existing chemical risk evaluation under TSCA, EPA must determine whether a chemical substance presents an unreasonable risk of injury to health or the environment, without consideration of costs or non-risk factors, including unreasonable risk to a potentially exposed or susceptible subpopulation identified as relevant to the risk evaluation, under the conditions of use. In this action, EPA proposes to rescind or revise certain 2024 amendments to the procedural framework rule to effectuate the best reading of the statute and ensure that the procedural framework rule does not impede the timely completion of risk evaluations or impair the effective and efficient protection of health and the environment.","document_number":"2025-18431","html_url":"https://www.federalregister.gov/documents/2025/09/23/2025-18431/procedures-for-chemical-risk-evaluation-under-the-toxic-substances-control-act-tsca","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-09-23/pdf/2025-18431.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-18431.pdf?1758545119","publication_date":"2025-09-23","agencies":[{"raw_name":"ENVIRONMENTAL PROTECTION AGENCY","name":"Environmental Protection Agency","id":145,"url":"https://www.federalregister.gov/agencies/environmental-protection-agency","json_url":"https://www.federalregister.gov/api/v1/agencies/145","parent_id":null,"slug":"environmental-protection-agency"}],"excerpts":"Bottle <span class=\"match\">Manufacturing</span> (NAICS code 326160); \n • Plastics Plumbing Fixture <span class=\"match\">Manufacturing</span> (NAICS code 326191); \n • All Other Plastics <span class=\"match\">Product</span> <span class=\"match\">Manufacturing</span> (NAICS code 326199); \n • Tire <span class=\"match\">Manufacturing</span> (except Retreading) (NAICS code 326211); \n • Tire Retreading (NAICS code 326212); \n • Rubber and Plastics Hoses and Belting <span class=\"match\">Manufacturing</span> (NAICS code 326220); \n • Rubber <span class=\"match\">Product</span> <span class=\"match\">Manufacturing</span> for Mechanical Use (NAICS code 326291); \n • All Other Rubber <span class=\"match\">Product</span> <span class=\"match\">Manufacturing</span> (NAICS code 326299); \n • Pottery, Ceramics, and Plumbing Fixture <span class=\"match\">Manufacturing</span> (NAICS"}]}